A new result shows that just about anyone at risk for Alzheimer’s – and that’s most of us – can change the trajectory of ...

A viral TikTok from fitness coach Eugene Teo helped rebrand a 2007 Japanese study into a time-saving walking trend. But ...

New research builds on evidence that diet, certain brain training exercises and physical activity can delay the decline of ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

K-Bio showcases AI and protein removal advancements for dementia at Toronto conference Innovations in dementia treatment ...

A ground-breaking study gives those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The researchers reported a significant improvement in global cognition ...

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

South Korean pharmaceutical and biotech companies are presenting their latest Alzheimer’s research at the world’s largest ...

ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. As a new generation of ...

The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease.